TrialRheumatology (Oxford, England)2024

Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease.

Yannick Allanore et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.